Alyteserin-2a [A10W]

General Information


DCTPep ID  DCTPep02102

Peptide Name   Alyteserin-2a [A10W]

Sequence  ILGKLLSTAWGLLSNL

Sequence Length  16

UniProt ID  Not available

PubChem CID  Not available

Origin  Synthetic (Derived from Alyteserin-2a)

Type  Synthetic peptide

Classification

  

ACP Tumor active peptide



Activity Information


Cell Line Disease Activity Assay Testing Time Literature
A549 Lung adenocarcinoma LC50=7 μM CellTiter-Glo Luminescent Cell Viability assay 24 h 1

Hemolytic Activity  Human erythrocytes: 50% Hemolysis=11 µM

Normal (non-cancerous) Cytotoxicity  Not available

Target  Not available

Affinity  Not available

Mechanism  Not available



Structure Information


PDB ID  Not available

Predicted Structure  DCTPep02102

(Please note that there is the predicted structure, predicted by AlphaFold)

Helicity  Not available

Linear/Cyclic  Linear

Disulfide/Other Bond  Not available

N-terminal Modification  Free

C-terminal Modification  Amidation

Other Modification  None

Chiral  L



Physicochemical Information


Formula  C80H135N19O21

Absent amino acids  CDEFHMPQRVY

Theoretical pI  8.75

Acidic residues  0

Basic residues  1

Polar residues  6

Molecular weight (Average)  1699.07

Molecular weight (Monoisotopic)  1698.01

Common amino acids  L

Net charge  1

Instability index (II)  4.32

Aliphatic index  176.88

Grand average of hydropathicity (GRAVY)  1.106

Half Life 
  20 hours (mammalian reticulocytes, in vitro).
  30 min (yeast, in vivo).
  >10 hours (Escherichia coli, in vivo).

Extinction coefficients 
  Ext. coefficient 5500
  Abs 0.1% (=1 g/l) 3.237

Amino acid distribution



Literature Information


Literature 1

Pubmed ID 22965637

Title  Transformation of the naturally occurring frog skin peptide, alyteserin-2a into a potent, non-toxic anti-cancer agent

Doi 10.1007/s00726-012-1395-7

Year  2013

Patent

Patent ID Not available

Patent Title  Not available

Other Iinformation  Not available

Other Published ID  Not available




DBAASP ID  DBAASPS_4369

DCTPep is developed by Dr.Zheng's team.